UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049826 |
|---|---|
| Receipt number | R000056368 |
| Scientific Title | Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer: Prospective observational study. |
| Date of disclosure of the study information | 2022/12/19 |
| Last modified on | 2025/02/12 15:59:35 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer: Prospective observational study.
Acronym
Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer
Scientific Title
Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer: Prospective observational study.
Scientific Title:Acronym
Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer
Region
| Japan |
Condition
Condition
Biliary tract cancer
Classification by specialty
| Hepato-biliary-pancreatic medicine |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
Efficacy of transpapillary biopsies for multi- gene panel testing of biliary tract cancer.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Appropriate sampling rate
1.Tumor ratio: 20% or more
2.DNA concentration: 1.0 ng/mL or more
3.DIN (DNA Integrity Number) value: 2 or more
Key secondary outcomes
1. Tumor ratio
2. Section surface area
3. DNA concentration
4. Estimated Nucleic Acid Abundance
5. DIN value
6. Procedural success rate
7. Adverse event
8. Success rate of multi-gene panel testing
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1. Patients need to examination and treatment by ERCP for suspected biliary tract cancer
2. Possible to get written informed consent from patients
3. Ages 20 and older
Key exclusion criteria
1. Patients with performance status 3 or 4
2. Patients with severe complications to other organs
3. Patients with severe coagulation dysfunction
4. Patients judged inappropriate by chief medical examiner
Target sample size
30
Research contact person
Name of lead principal investigator
| 1st name | Kazuyuki |
| Middle name | |
| Last name | Matsumoto |
Organization
Okayama University Hospital
Division name
Department of Endoscopy
Zip code
700-8558
Address
2-5-1 Shikata-cho,Kita-ku Okayama-city Okayama
TEL
086-235-7219
matsumoto.k@okayama-u.ac.jp
Public contact
Name of contact person
| 1st name | Kazuya |
| Middle name | |
| Last name | Miyamoto |
Organization
Okayama University Hospital
Division name
Department of Gastroenterology
Zip code
700-8558
Address
2-5-1 Shikata-cho,Kita-ku Okayama-city Okayama
TEL
086-235-7219
Homepage URL
ttpcx442@yahoo.co.jp
Sponsor or person
Institute
Okayama university hospital
Institute
Department
Personal name
Funding Source
Organization
Okayama university hospital
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Okayama University Ethics Review Committee
Address
2-5-1 Shikata-cho,Kita-ku Okayama-city Okayama
Tel
086-235-6938
mae6605@adm.okayama-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 12 | Month | 19 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2022 | Year | 12 | Month | 19 | Day |
Date of IRB
| 2022 | Year | 12 | Month | 19 | Day |
Anticipated trial start date
| 2022 | Year | 12 | Month | 19 | Day |
Last follow-up date
| 2025 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Primaly endopoint
Appropriate sampling rate
1.Tumor ratio: 20% or more
2.DNA concentration: 1.0 ng/mL or more
3.DIN (DNA Integrity Number) value: 2 or more
Secondary endopoints
1. Tumor ratio
2. Section surface area
3. DNA concentration
4. Estimated Nucleic Acid Abundance
5. DIN value
6. Procedural success rate
7. Adverse event
8. Success rate of multi-gene panel testing
Management information
Registered date
| 2022 | Year | 12 | Month | 19 | Day |
Last modified on
| 2025 | Year | 02 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056368
